Researchers have identified a promising new diagnostic tool for progressive supranuclear palsy (PSP), a rare neurodegenerative condition affecting movement and balance. The dual-line midbrain PSP index (DMPI), a novel linear MRI marker, accurately differentiates PSP from Parkinson disease and other parkinsonian syndromes, even in early stages.
In a secondary analysis of 2,111 participants across international cohorts, the DMPI achieved an area under the receiver operating characteristic curve (AUC) of 0.97. This outperformed established metrics like the midbrain area measurement, which scored 0.95. Crucially, the DMPI reduced diagnostic uncertainty, with only 7.97% of cases falling into a grey zone.
The study included data from the University of Catanzaro and other global institutions between 2006 and 2024. While further clinical validation is required to integrate DMPI into routine practice, its robust performance suggests it could significantly streamline diagnostic decision-making for patients presenting with complex parkinsonian symptoms.